ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03525678
Recruitment Status : Recruiting
First Posted : May 16, 2018
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage of all cancers and for 10% of all hematologic malignancies. Subjects with relapsed/refractory multiple myeloma (RRMM) will be included in this study, to evaluate the efficacy and safety of GSK2857916 monotherapy. Subjects will be treated with GSK2857916 monotherapy until disease progression or unacceptable toxicity and will be followed for Progression Free Survival (PFS) and Overall survival (OS). The subjects will be randomized to receive either frozen GSK2857916 at the dose of 2.5 milligram per kilogram (mg/kg) or 3.4 mg/kg Intravenous (IV). There will be an independent cohort of subjects who will receive a lyophilized configuration of GSK2857916. Approximately 155 subjects will be enrolled in the study of which 130 subjects will be enrolled to receive frozen GSK2857916 and 25 subjects will be enrolled in the independent lyophilized drug product cohort. The subjects who discontinued from the study other than Progressive disease (PD), disease evaluation will continue to be performed at 3-week intervals until confirmed PD, death, start of a new anticancer treatment, withdrawal of consent, or end of the study whichever occurs first.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: GSK2857916 frozen Drug: GSK2857916 lyophilized Other: NEI-VFQ-25 Questionnaire Other: OSDI Questionnaire Other: EORTC QLQ-C30 Questionnaire Other: EORTC QLQ-MY20 Questionnaire Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 155 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Actual Study Start Date : June 18, 2018
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Subjects receiving frozen 2.5 mg/kg GSK2857916
Subjects will be randomized in 1:1 ratio to receive either 2.5 or 3.4 mg/kg frozen liquid GSK2857916. Subjects will administer frozen liquid GSK2857916 via infusion pump for once in every 3 weeks.
Drug: GSK2857916 frozen
GSK2857916 will be available as frozen liquid or lyophilized powder. Frozen liquid will be available as 30 mg/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. GSK2857916 will be administered as IV solution over 30 minutes. Frozen GSK2857916 will be diluted 0.9 percent saline and administered via infusion pump.

Other: NEI-VFQ-25 Questionnaire
The NEI-VFQ-25 Questionnaire consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question

Other: OSDI Questionnaire
The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning.

Other: EORTC QLQ-C30 Questionnaire
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ QoL scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100.

Other: EORTC QLQ-MY20 Questionnaire
EORTC QLQ-MY20 is a supplement to the QLQ-C30. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image.

Experimental: Subjects receiving frozen 3.4 mg/kg GSK2857916
Subjects will be randomized in 1:1 ratio to receive either 2.5 or 3.4 mg/kg frozen liquid GSK2857916. Subjects will administer frozen liquid GSK2857916 via infusion pump for once in every 3 weeks.
Drug: GSK2857916 frozen
GSK2857916 will be available as frozen liquid or lyophilized powder. Frozen liquid will be available as 30 mg/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. GSK2857916 will be administered as IV solution over 30 minutes. Frozen GSK2857916 will be diluted 0.9 percent saline and administered via infusion pump.

Other: NEI-VFQ-25 Questionnaire
The NEI-VFQ-25 Questionnaire consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question

Other: OSDI Questionnaire
The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning.

Other: EORTC QLQ-C30 Questionnaire
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ QoL scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100.

Other: EORTC QLQ-MY20 Questionnaire
EORTC QLQ-MY20 is a supplement to the QLQ-C30. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image.

Experimental: Subjects receiving lyophilized GSK2857916
Subjects in lyophilized arm will receive lyophilized GSK2857916 once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
Drug: GSK2857916 lyophilized
GSK2857916 will be available as frozen liquid or lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 2.5 or 3.4 mg/kg. GSK2857916 will be administered as IV solution over 30 minutes. Lyophilized GSK2857916 will reconstituted using water for injection.

Other: NEI-VFQ-25 Questionnaire
The NEI-VFQ-25 Questionnaire consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question

Other: OSDI Questionnaire
The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning.

Other: EORTC QLQ-C30 Questionnaire
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ QoL scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100.

Other: EORTC QLQ-MY20 Questionnaire
EORTC QLQ-MY20 is a supplement to the QLQ-C30. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image.




Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: Every 3 weeks up to 2 years ]
    ORR, defined as the percentage of subjects with a confirmed partial response (PR) or better (that is [i.e.], PR, very good partial response [VGPR], complete response [CR] and stringent complete response [sCR]), according to the 2016 International Myeloma Working Group (IMWG) Response Criteria by Independent Review Committee (IRC).


Secondary Outcome Measures :
  1. Clinical benefit rate (CBR) [ Time Frame: Every 3 weeks up to 2 years ]
    CBR is defined as the percentage of subjects with a confirmed minimal response (MR) or better according to the 2016 IMWG IRC.

  2. Duration of response (DoR) [ Time Frame: Every 3 weeks up to 2 years ]
    DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG; or death due to PD occurs among subjects who achieve an overall response, i.e., confirmed PR or better.

  3. Time to response [ Time Frame: Every 3 weeks up to 2 years ]
    Time to response is defined as the time between the date of first dose and the first documented evidence of response (PR or better).

  4. Progression free survival [ Time Frame: Every 3 weeks up to 2 years ]
    Progression free survival is defined as the time from first dose until the earliest date of documented disease progression (PD) per IMWG, or death due to any cause.

  5. Time to progression [ Time Frame: Every 3 weeks up to 2 years ]
    Time to progression is defined as the time from first dose until the earliest date of documented PD per IMWG, or death due to PD.

  6. Overall survival [ Time Frame: Every 3 weeks up to 2 years ]
    Overall survival is defined as the time from first dose until death due to any cause.

  7. Number of subjects with abnormal hematology parameters [ Time Frame: Every 3 weeks up to 2 years ]
    Laboratory assessment for hematology parameters will include Platelet count, hemoglobin (Hgb), Red blood cell (RBC) count, hematocrit, reticulocyte count, RBC indices like mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). White blood cell (WBC) count with differential will include neutrophils, lymphocytes, monocytes, eosinophils and basophils.

  8. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Every 3 weeks up to 2 years ]
    Laboratory assessment for clinical chemistry parameters will include blood urea nitrogen (BUN), potassium, calcium, sodium, creatinine, glucose, magnesium, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline phosphate, total protein, total and direct bilirubin, albumin, uric acid, lactate dehydrogenase (LDH), gamma glutamyl transpeptidase (GGT), Creatine kinase (CK), total bicarbonate, albumin/ creatinine ratio, Estimated glomerular filtration rate (eGFR), chloride, and phosphorus.

  9. Number of subjects with abnormal physical examination parameters [ Time Frame: Every 3 weeks up to 2 years ]
    Physical examination parameters will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities.

  10. Number of subjects with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) assessment [ Time Frame: Every 3 weeks up to 2 years ]
    SBP and DBP will be measured after 5 minutes rest.

  11. Number of subjects with abnormal pulse rate [ Time Frame: Every 3 weeks up to 2 years ]
    Pulse rate will be measured after 5 minutes rest.

  12. Number of subjects with abnormal body temperature [ Time Frame: Every 3 weeks up to 2 years ]
    Temperature will be measured after 5 minutes rest.

  13. Number of subjects with adverse events (AEs), serious AEs (SAEs) and AEs of special interest (AESI) [ Time Frame: Up to 2 years ]
    An AE is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death due to PD, is life-threatening, may require hospitalization or prolongation of existing hospitalization, result in persistent disability/incapacity, or may led to any congenital anomaly or birth defect. AESI for GSK2857916 are corneal events, thrombocytopenia and infusion related reactions.

  14. Number of subjects with abnormal ocular findings [ Time Frame: Up to 2 years ]
    Ocular examination for the subjects will include procedures for corrected visual acuity, current glasses, pupillary examination, extra ocular muscular movements, intra-ocular pressure, examination of tear film, and examination of cornea.

  15. Area under the curve (AUC) of GSK2857916 [ Time Frame: Pre-dose within 30 minutes prior to start of infusion (SOI) and End of Infusion (EOI) on Cycle (C)1; Pre-dose, 2 hours after SOI on C2, C6, C9, and C12 and at EOI; every 6 subsequent cycles at pre-dose and at EOT ]
    Blood samples will be collected at indicated time points for analysis of AUC

  16. Maximum plasma concentration (Cmax) of GSK2857916 [ Time Frame: Pre-dose within 30 minutes prior to start of infusion (SOI) and End of Infusion (EOI) on Cycle (C)1; Pre-dose, 2 hours after SOI on C2, C6, C9, and C12 and at EOI; every 6 subsequent cycles at pre-dose and at EOT ]
    Blood samples will be collected at indicated time points for analysis of Cmax

  17. Time of occurrence of Cmax (Tmax) of GSK2857916 [ Time Frame: Pre-dose within 30 minutes prior to start of infusion (SOI) and End of Infusion (EOI) on Cycle (C)1; Pre-dose, 2 hours after SOI on C2, C6, C9, and C12 and at EOI; every 6 subsequent cycles at pre-dose and at EOT ]
    Blood samples will be collected at indicated time points for analysis of tmax

  18. Terminal phase half-life (T1/2) of GSK2857916 [ Time Frame: Pre-dose within 30 minutes prior to start of infusion (SOI) and End of Infusion (EOI) on Cycle (C)1; Pre-dose, 2 hours after SOI on C2, C6, C9, and C12 and at EOI; every 6 subsequent cycles at pre-dose and at EOT ]
    Blood samples will be collected at indicated time points for analysis of t1/2

  19. Incidence and titers of anti-drug antibodies (ADAs) [ Time Frame: Up to 2 years ]
    Blood samples will be collected at indicated time points for analysis of ADAs using electrochemiluminescent immunoassay

  20. Number of subjects with symptomatic AEs measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [ Time Frame: Every 3 weeks up to 2 years ]
    The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It provides systematic and flexible tool for descriptive reporting of symptomatic treatment side effects in cancer clinical trials.

  21. Number of subjects with symptomatic AEs measured by National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) [ Time Frame: Every 3 weeks up to 2 years ]
    The NEI-VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question.

  22. Number of subjects with symptomatic AEs measured by Ocular Surface Disease Index (OSDI) [ Time Frame: Every 3 weeks up to 2 years ]
    The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning.

  23. Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score [ Time Frame: Every 6 weeks up to 2 years ]
    The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

  24. Change in EORTC QLQ- 20-item Multiple Myeloma module (MY-20) score [ Time Frame: Every 6 weeks up to 2 years ]
    The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in subjects with MY. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects provide signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Male or female, 18 years or older.
  • Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Histologically or cytologically confirmed diagnosis of MM as defined according to International Myeloma Working Group (IMWG). The subject has undergone stem cell transplant or is considered transplant ineligible and has failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (example [e.g.], daratumumab) alone or in combination, and is refractory to an Immunomodulatory drugs (IMiD) (that is [i.e.], lenalidomide or pomalidomide), and to a proteasome inhibitor (i.e., bortezomib, ixazomib or carfilzomib).
  • The subject has measurable disease with at least one of the following: Serum M-protein >=0.5 gram per deciliter (g/dL) (>=5 gram per Liter [g/L]); Urine M-protein >=200 milligram per 24 hours (mg/24h); Serum Free light chain (FLC) assay: Involved FLC level >=10 mg/dL (>=100 mg/L) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • Subjects with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: transplant was >100 days prior to study enrolment; no active infection(s); subjects meets the remainder of the eligibility criteria outlined in this protocol.
  • Subjects with adequate organ system functions as defined follows: Absolute neutrophil count (ANC) >=1.0 X 10^9/L; Hemoglobin >=8.0 g/dL; Platelets>= 50 X 10^9/L; Total bilirubin <=1.5X Upper limit of normal (ULN). Isolated bilirubin >=1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent); Alanine aminotransferase (ALT) <=2.5X ULN; Estimated glomerular filtration rate (eGFR) >=30 milliliter per minute per 1.73 meter square (mL/min/m^2); Spot urine (albumin/creatinine ratios [spot urine]) < 500 milligram per gram (mg/g) (56 mg per millimoles [mg/mmol]); Left ventricular ejection fraction (LVEF) >= 45 percent.
  • Female subjects: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female subject is eligible to participate if she is not pregnant or breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, during the intervention period and for at least 80 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.
  • Male subjects are eligible to participate if they agree to the following during the intervention period and for at least 140 days: Refrain from donating sperm; Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1 percent per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
  • All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03, must be <=Grade 1 at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.
  • For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

  • Systemic anti-myeloma therapy within <14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
  • Symptomatic amyloidosis, active 'polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes' (POEMS) syndrome, active plasma cell leukemia at the time of screening.
  • Prior allogeneic stem cell transplant.
  • Current corneal epithelial disease except mild punctate keratopathy.
  • Use of an investigational drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs. Prior BCMA targeted therapy.
  • Evidence of active mucosal or internal bleeding.
  • Any major surgery within the last four weeks.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if subject otherwise meets entry criteria.
  • Malignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).
  • Evidence of cardiovascular risk including any of the following: Corrected QT interval Fridericia (QTcF) interval >=470 milliseconds (msecs); Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening; Class III or IV heart failure as defined by the New York Heart Association functional classification system (NYHA); Uncontrolled hypertension.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916, or any of the components of the study treatment.
  • Pregnant or lactating female.
  • Active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Known Human Immunodeficiency Virus (HIV) infection.
  • Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at screening or within 3 months prior to first dose of study treatment.
  • Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment. Subjects with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03525678


Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

  Show 52 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03525678     History of Changes
Other Study ID Numbers: 205678
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Relapsed / refractory multiple myeloma
Antibody-drug conjugate
Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events
Quality of Life Questionnaire 20-item Multiple Myeloma module
Multiple Myeloma
Quality of Life Questionnaire 30-item Core module

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Immunoglobulins
Proteasome Inhibitors
Immunologic Factors
Physiological Effects of Drugs
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action